US2020300843A1PendingUtilityA1

Clozapine Immunoassay

Assignee: SALADAX BIOMEDICAL INCPriority: May 24, 2011Filed: Jun 12, 2020Published: Sep 24, 2020
Est. expiryMay 24, 2031(~4.9 yrs left)· nominal 20-yr term from priority
G01N 33/94C07D 243/38C07K 2317/33C07D 403/12C07K 16/44G01N 33/5308A61P 25/18
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Novel conjugates and immunogens derived from clozapine and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of clozapine in biological fluids.

Claims

exact text as granted — not AI-modified
1 - 10 . (canceled) 
     
     
         11 . An antibody which binds selectively to clozapine and does not substantially bind to N-desmethylclozapine and clozapine-N-oxide. 
     
     
         12 . The antibody of  claim 11 , wherein said antibody is derived from mice, sheep, rabbits or rats. 
     
     
         13 . The antibody of  claim 11 , wherein said antibody is a monoclonal antibody. 
     
     
         14 . The antibody of  claim 11 , wherein said antibody is derived from an immunogenic carrier having a reactive amino or thiol group polymer conjugated to a compound selected from the group consisting of compounds of the formula: 
       
         
           
           
               
               
           
         
         wherein B is: —(C═O)—, —(C═O)—NH—, —(C═O)—O—, —CH2-; 
         Y is an organic spacing group; 
         X is a terminal functional group capable of binding 
         to a polyamine polymer; and 
         p is an integer from 0 to 1; 
         or a thereof. 
       
     
     
         15 . The antibody of  claim 14 , wherein the carrier contains a thiol group and X in the compound which is conjugated to the immunogenic polymer is a functional group capable of reacting with said thiol. 
     
     
         16 . The antibody of  claim 15 , wherein X in said compound is 
       
         
           
           
               
               
           
         
       
     
     
         17 . The antibody of  claim 16 , wherein Y in said compound is lower alkylene. 
     
     
         18 . The antibody of  claim 17 , wherein the immunogenic carrier contains as the functional group: 
       
         
           
           
               
               
           
         
       
       wherein v is an integer from 1 to 6. 
     
     
         19 . The antibody of  claim 18 , wherein said antibody is derived from mice, sheep, rabbits or rats. 
     
     
         20 - 38 . (canceled)

Join the waitlist — get patent alerts

Track US2020300843A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.